Titre:
  • In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Auteur:Meraviglia, S; Eberl, M; Vermijlen, David; Todaro, M; Buccheri, S; Cicero, G; La Mendola, C; Guggino, G; D'Asaro, M; Orlando, V; Scarpa, F; Roberts, Allen; Caccamo, N; Stassi, G; Dieli, F; Hayday, A C
Informations sur la publication:Clinical and experimental immunology, 161, 2, page (290-297)
Statut de publication:Publié, 2010-08
Sujet CREF:Immunologie
Mots-clés:cytokines
cytotoxicity
immunotherapy
metastatic breast cancer
Vγ9Vδ2 T cells
MeSH keywords:Adjuvants, Immunologic -- adverse effects -- pharmacology -- therapeutic use
Aged
Antigens, CD27 -- metabolism
Antigens, CD45 -- metabolism
Breast Neoplasms -- blood -- immunology -- therapy
Cell Proliferation -- drug effects
Chemokines -- blood
Cytokines -- blood
Diphosphonates -- adverse effects -- pharmacology -- therapeutic use
Disease Progression
Esterases -- metabolism
Female
Hemiterpenes -- pharmacology
Humans
Imidazoles -- adverse effects -- pharmacology -- therapeutic use
Immunotherapy -- methods
Interferon-gamma -- metabolism
Interleukin-2 -- adverse effects -- pharmacology -- therapeutic use
Lymphocyte Activation -- drug effects
Lymphocyte Count
Lysine -- analogs & derivatives -- metabolism
Middle Aged
Mucin-1 -- blood
Organophosphorus Compounds -- pharmacology
Receptors, Antigen, T-Cell, gamma-delta -- metabolism
Remission Induction
Salvage Therapy
T-Lymphocyte Subsets -- cytology -- drug effects -- immunology -- metabolism
TNF-Related Apoptosis-Inducing Ligand -- metabolism
Treatment Outcome
Note générale:Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
FLWIN
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0009-9104
info:doi/10.1111/j.1365-2249.2010.04167.x
info:pii/CEI4167
info:scp/77954652637
info:pmid/20491785
PMC2909411